We are live on ! Find out more
SRPT icon

Sarepta Therapeutics

177 hedge funds and large institutions have $1.08B invested in Sarepta Therapeutics in 2016 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 63 increasing their positions, 54 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

72.29% more ownership

Funds ownership: 0%72.29% (+72%)

17% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 54

9% more call options, than puts

Call options by funds: $212M | Put options by funds: $195M

5% less funds holding

Funds holding: 186177 (-9)

14% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 50

58% less capital invested

Capital invested by funds: $2.59B → $1.08B (-$1.51B)

64% less funds holding in top 10

Funds holding in top 10: 114 (-7)

Holders
177
Holders Change
-9
Holders Change %
-4.84%
% of All Funds
4.42%
Holding in Top 10
4
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-63.64%
% of All Funds
0.1%
New
43
Increased
63
Reduced
54
Closed
50
Calls
$212M
Puts
$195M
Net Calls
+$17.1M
Net Calls Change
+$274M
Name Holding Trade Value Shares
Change
Change in
Stake
RJA
126
Raymond James & Associates
Florida
$279K -$452K -11,244 -52%
SSA
127
Schonfeld Strategic Advisors
New York
$277K -$1.76M -43,938 -81%
AG
128
Advisor Group
Arizona
$267K +$2.69K +67 +0.7%
Principal Financial Group
129
Principal Financial Group
Iowa
$256K +$69.1K +1,720 +23%
NIT
130
NumerixS Investment Technologies
British Columbia, Canada
$255K +$373K +9,293 New
SGAM
131
Smith Group Asset Management
Texas
$254K +$372K +9,260 New
SCM
132
Sterling Capital Management
North Carolina
$252K +$370K +9,205 New
FAAS
133
First Allied Advisory Services
California
$248K +$1.04K +26 +0.3%
LP
134
LGL Partners
Pennsylvania
$244K
HSBC Holdings
135
HSBC Holdings
United Kingdom
$240K +$351K +8,750 New
SFP
136
Shepherd Financial Partners
Massachusetts
$233K +$335K +8,333 New
ECM
137
Endurant Capital Management
California
$230K +$337K +8,400 New
RJFSA
138
Raymond James Financial Services Advisors
Florida
$221K -$116K -2,898 -26%
BCA
139
Benchmark Capital Advisors
New York
$206K +$100K +2,500 +50%
JCM
140
Jafra Capital Management
New York
$206K +$301K +7,500 New
G
141
GenTrust
Florida
$205K +$300K +7,461 New
Royal Bank of Canada
142
Royal Bank of Canada
Ontario, Canada
$168K +$131K +3,256 +113%
CCMH
143
Cornerstone Capital Management Holdings
New York
$155K +$137K +3,400 +148%
Canada Life
144
Canada Life
Manitoba, Canada
$136K
CSS
145
Cubist Systematic Strategies
Connecticut
$135K +$187K +4,665 +1,703%
TRCT
146
Tower Research Capital (TRC)
New York
$132K +$144K +3,587 +293%
WAM
147
Wolverine Asset Management
Illinois
$104K -$4.02K -100 -3%
PCM
148
Prelude Capital Management
New York
$102K +$65.2K +1,624 +77%
CWG
149
C WorldWide Group
Denmark
$91K +$133K +3,304 New
WEC
150
Winslow Evans & Crocker
Massachusetts
$54.9K -$56.2K -1,400 -41%

SRPT Hedge Fund Activity: Q4 2016 in Review

177 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2016, worth a combined $1.08B — down 58% from $2.59B a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of SRPT and 43 opened new positions — a net loss of 7 holders — while 54 trimmed existing stakes and 63 added.

The largest buyer was Carlson Capital, opening a new position worth an estimated $88.5M. The largest seller was Point72 Asset Management, cutting an estimated $77M.

  • 177 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2016, down from 186 in Q3 2016.
  • Funds reported $1.08B of Sarepta Therapeutics stock for Q4 2016, down 58% quarter-over-quarter.
  • 43 funds opened new Sarepta Therapeutics positions in Q4 2016 and 50 closed out, a net change of -7 holders.
  • The largest Sarepta Therapeutics buyer in Q4 2016 was Carlson Capital, an estimated $88.5M added.
  • The largest Sarepta Therapeutics seller in Q4 2016 was Point72 Asset Management, an estimated $77M sold.

Based on aggregated 13F filings for Q4 2016.